Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Apogee Therapeutics, Inc. Common Stock (APGE) operate in?
Apogee Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Apogee Therapeutics, Inc. Common Stock (APGE) current stock price?
As of the latest data, Apogee Therapeutics, Inc. Common Stock stock price is $134.45, with a previous close of $134.55. Apogee Therapeutics, Inc. Common Stock lost -$0.10 in the last trading session, representing a -0.07% loss.
What is Apogee Therapeutics, Inc. Common Stock (APGE) current market capitalization?
Apogee Therapeutics, Inc. Common Stock market cap is approximately 8.36 billion.
What is Apogee Therapeutics, Inc. Common Stock (APGE) Earnings Per Share (EPS)?
The trailing EPS is -$4.33, and the forward EPS is -$5.23.
What is Apogee Therapeutics, Inc. Common Stock (APGE) EBITDA?
Apogee Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -84.20 million.
Does Apogee Therapeutics, Inc. Common Stock (APGE) pay dividends?
No. Apogee Therapeutics, Inc. Common Stock does not pay a dividend.
What is Apogee Therapeutics, Inc. Common Stock (APGE) beta (volatility) score?
Apogee Therapeutics, Inc. Common Stock has a beta of 0.343, indicating lower volatility than the overall market.
